Related Experiment Videos
Cardiac transplantation of skeletal myoblasts for heart failure
1Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA. dataylor@duke.edu
Insights
Heart failure treatment shows promise with cardiac cell transplantation. Myoblast cell therapy may regenerate heart muscle after myocardial infarction, restoring function and preventing heart failure progression.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cell Biology
Background:
- Heart failure is a growing cardiovascular problem, often resulting from myocardial infarction.
- Current treatments for myocardial infarction have plateaued due to the inability to address cardiomyocyte death.
- Cellular transplantation offers a novel therapeutic approach for cardiac repair.
Purpose of the Study:
- To review the current status of intracardiac myoblast transplantation for cardiac repair.
- To discuss the future potential and clinical applications of myoblast transplantation.
- To provide insights into unanswered questions regarding this emerging therapy.
Main Methods:
- Review of pre-clinical studies and clinical trials involving cell transplantation for cardiac repair.
- Focus on myoblast progenitor cells as a widely studied cell type.
- Analysis of cell engraftment, regeneration capabilities, and functional recovery in infarcted hearts.
Main Results:
- Myoblast transplantation has shown promise in animal models, with cells capable of engrafting and regenerating infarcted areas.
- Pre-clinical studies suggest potential for adapting to the cardiac environment and restoring function.
- Several cell types have been proposed, with myoblasts being the most extensively researched.
Conclusions:
- Intracardiac myoblast transplantation is a promising therapeutic strategy for myocardial infarction.
- Further research is needed to address remaining questions for successful clinical translation.
- This approach holds potential for preventing the transition to heart failure and improving cardiac function.
Abstract:
Heart failure has become the most prevalent cardiovascular syndrome, and its incidence continues to increase. Most cases of heart failure develop as a result of myocardial infarction. Although current treatment modalities have brought us the opportunity to reduce mortality and morbidity after myocardial infarction, our progress has plateaued due to our inability to treat the underlying problem, death of cardiomyocytes. Recently, a new option has emerged. Transplantation of undifferentiated cells into the damaged heart is a promising new treatment modality. These cells may have the capability of adapting to the cardiac environment, regenerating the damaged muscle, restoring cardiac function and preventing transition to heart failure. During the last few years many cell types have been proposed for cardiac repair and promising pre-clinical studies have moved some of these into the clinic. The most widely studied cell type is the progenitor cell of adult muscle, or the myoblast. When transplanted into the heart myoblasts are able to engraft and to a large degree regenerate the infarcted area. Although the feasibility of myoblast transplantation has been proven in animal models of infarction, many questions remain unanswered. In this review we will try to present an overview of where intracardiac myoblast transplantation stands and where it is heading. We also provide our insight into the future potential for myoblast transplantation clinically.